Cards Acccepted | 5% OFF Crypto | 3rd Party Testing | FREE Worldwide Shipping $400+
Menu
Cart
Tesamorelin 5 mg lyophilized vial
lyophilized peptide vial box (white cap)
tesamorelin certificate of analysis
tesamorelin HPLC

Tesamorelin 5mg – 10 Vial Box

$365.00

Cost per vial $: 36.5

Buy tesamorelin 5 mg (one 10-vial box). All orders are shipped wholesale in unbranded packaging. Worldwide 7 – 14 day shipping to the USA, UK, AUS & NZ.

Bulk discounts
Quantity Bulk Discount Price
25%$346.75
3-57%$339.45
6-1010%$328.50
SKU: TES5Category:

Description

Tesamorelin is a synthetic peptide that encourages the body to produce and release more growth hormone by mimicking natural signals. It’s commonly used to improve body composition and metabolic health. Approved primarily for reducing excess abdominal fat in people with HIV-related lipodystrophy, tesamorelin can contribute to a range of benefits associated with increased growth hormone levels. Tesamorelin is the generic peptide version of Egrifta.

Minimum order quantity: one box (10 vials x 5 mg). Photo for illustration purposes only.

Additional information

Purity

≥99.0%

Molar Mass

5135.86 g·mol

Molecular Formula

C₂₂₁H₃₆₆N₇₂O₆₇S

Sequence

Tyr-D-Ala-Ala-Ala-Gly-Glu-Ser-Ile-His-Lys-Leu-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Lys-Gln-Arg-Ala-Arg-Glu-Gly-Ser

Cost per vial $

36.5

  1. Wang, Ying, and Brian Tomlinson. "Tesamorelin, a human growth hormone releasing factor analogue." Expert Opinion on Investigational Drugs 18.3 (2009): 303-310.
  2. Grunfeld, Carl, Argyris Dritselis, and Peter Kirkpatrick. "Tesamorelin." Nature Reviews Drug Discovery 10.2 (2011): 95-97.
  3. Clemmons, David R., Sam Miller, and Jean-Claude Mamputu. "Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial." PLoS One 12.6 (2017): e0179538.
  4. Falutz, Julian, et al. "Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation." Aids 22.14 (2008): 1719-1728.
  5. Stanley, Takara L., et al. "Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial." The Lancet HIV 6.12 (2019): e821-e830.
  6. Falutz, Julian, et al. "Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data." The Journal of Clinical Endocrinology & Metabolism 95.9 (2010): 4291-4304.
  7. Stanley, Takara L., et al. "Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial." Jama 312.4 (2014): 380-389.
  8. Spooner, Linda M., and Jacqueline L. Olin. "Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy." Annals of Pharmacotherapy 46.2 (2012): 240-247.

Tesamorelin CoA 2023

Tesamorelin HPLC

Related products